|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly to Submit Oral GLP-1 for FDA Priority Review Program: Report
2
GCC Emerges as a New Strategic Anchor for Global Venture Capital
3
Tylenol Maker Sued While Kennedy Says No ‘Sufficient’ Evidence for Autism Link
4
Pharmaceutical Executive Daily: Novo Nordisk's Unsolicited Acquisition Proposal
5
